市場調查報告書
商品編碼
1465050
暴食症市場:按產品、最終用戶分類 - 2024-2030 年全球預測Binge Eating Disorder Market by Product (Diagnostics, Treatments), End-User (Hospitals, Specialty Clinics) - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
暴食症市場規模預計2023年為5.5642億美元,2024年達到5.8785億美元,預計2030年將達到8.3576億美元,複合年成長率為5.98%。
暴食症(BED)被認為是飲食障礙,其特徵是經常在短時間內反覆攝入大量食物,在暴食期間感到失控,隨後感到羞恥,痛苦等,體驗內疚。暴食的頻率和嚴重程度各不相同,被歸類為一種需要引起注意的嚴重心理健康狀況。人們越來越意識到和理解暴食症是一個嚴重的健康問題,越來越多的人正在尋求治療。此外,包括認知行為療法(CBT)、藥物療法和個人化治療在內的治療方案的進步為管理提供了有效的手段,並成為暴食症市場的關鍵促進因素。儘管有成長的希望,但缺乏對心理健康和飲食障礙的認知和恥辱阻礙了人們尋求治療。此外,某些地區高昂的治療費用和缺乏保險覆蓋對獲得有效治療方法構成了重大障礙。然而,將遠端醫療服務和用於自我管理的行動應用程式等先進技術整合到護理過程中,為偏遠和服務欠缺地區的患者提供了新的幫助方法。此外,持續的研究和開發正在產生新的治療藥物和治療性介入,擴大了可用治療選擇的範圍。
主要市場統計 | |
---|---|
基準年[2023] | 55642萬美元 |
預測年份 [2024] | 58785萬美元 |
預測年份 [2030] | 83576萬美元 |
複合年成長率(%) | 5.98% |
需要有效的診斷來準確識別產品 BED 和合併症
暴食症診斷領域主要涉及心理評估、身體檢查和實驗室檢查。準確和早期的診斷工具對於了解患者的飲食行為、病史和心理健康狀況至關重要。
暴食症的治療包括藥物治療、心理治療和支持團體/諮詢。托吡酯等抗驚厥藥物可以透過調節大腦中的神經傳遞途徑來穩定情緒並可能降低食慾。抗憂鬱症,包括選擇性血清素再回收抑制劑(SSRI),通常用於治療暴食症,反映了暴食症和情緒障礙的共病。理論上,抗憂鬱症藥物治療暴飲暴食的有效性源於其提高血清素水平、影響情緒並可能減少強迫性飲食行為的能力。認知行為療法(CBT)專注於識別和改變與暴飲暴食相關的負面思維模式和行為。 CBT 幫助人們制定應對策略,以控制暴飲暴食的衝動,提高自尊,並處理同時發生的心理問題,例如憂鬱症和焦慮。辯證行為療法(DBT)是認知行為療法的一種型態,它整合了正念、情緒調節、痛苦承受和人際互動有效性的策略。 DBT 在 BED 治療中的主要重點是幫助個人理解和接受他們的暴食行為,同時努力透過培養應對技能來改變這些行為。人際心理治療(IPT)是一種限時治療方法,專注於改善人際功能和溝通技巧。探討可能引發暴食事件的潛在人際問題,例如未解決的悲傷、角色衝突、角色轉換和人際溝通缺陷。
最終使用者:對於能夠提供滿足 BED 患者複雜需求所需的綜合服務的醫院,人們的偏好較高。
醫院在暴食症(BED)的治療和管理中發揮重要作用。最終使用者醫院採用多學科方法提供全面的護理,包括醫學評估、營養諮詢、精神支持和行為治療。醫院是首選,因為它們有能力提供即時醫療護理和後續治療計劃。專門治療飲食障礙的專業診所為暴食症患者提供有針對性的個人化照護。這些診所提供各種專業治療方法,包括認知行為療法 (CBT)、人際心理治療 (IPT)、辯證行為療法 (DBT) 和 BED 特定藥物管理。這些診所的專業性使人們能夠更深入地了解飲食障礙,並創造一個讓患者接受飲食障礙治療經驗豐富的專業人員的重症監護的環境。
區域洞察
在美洲,人們對暴食症的認知和診斷不斷提高,導致藥物和非藥物治療的大量採用,從而導致該地區的市場表現強勁。 FDA 對 BED 專用藥物的核准以及保險公司對治療療程的保險覆蓋正在促進成長。在 EMEA(歐洲、中東和非洲)地區,人們越來越認知到暴食症是一種獨特的醫療狀況,這正在影響市場表現。歐洲擁有先進的醫療保健系統和認知行為療法 (CBT) 等廣泛的治療選擇,是歐洲、中東和非洲地區暴食症市場成長的主要貢獻者。另一方面,由於意識和醫療基礎設施有限,中東和非洲地區的成長正在放緩。在亞太地區,由於人們對心理健康的認知不斷提高,人們對暴食症的認知及其治療市場正在逐漸擴大。然而,該地區面臨心理健康文化恥辱和缺乏專業醫療保健提供者等挑戰。
FPNV定位矩陣
FPNV 定位矩陣對於評估暴食症市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對暴食症市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.暴食症市場的市場規模和預測是多少?
2.在暴食症市場預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3. 暴食症市場的技術趨勢和法規結構是什麼?
4.暴食症市場主要供應商的市場佔有率是多少?
5. 進入暴食症市場的合適型態和策略手段是什麼?
[187 Pages Report] The Binge Eating Disorder Market size was estimated at USD 556.42 million in 2023 and expected to reach USD 587.85 million in 2024, at a CAGR 5.98% to reach USD 835.76 million by 2030.
Binge eating disorder (BED) is recognized as an eating disorder described by recurrent episodes of consuming large quantities of food, often quickly, accompanied by a feeling of loss of control during the bingeing and experiencing shame, distress, or guilt afterward. It differs from overeating in its frequency and severity, and it's classified as a significant mental health condition requiring attention. A growing awareness and understanding of BED as a significant health issue have led to more people seeking treatment. Additionally, advancements in treatment options, including cognitive behavioral therapy (CBT), medications, and personalized therapy sessions, have provided effective means for management, acting as a significant driver for the binge eating disorder market. Despite the growth prospects, a lack of awareness and the stigma associated with mental health and eating disorders hinders individuals from seeking treatment. Moreover, the high cost of therapy and lack of insurance coverage in some areas pose significant barriers to accessing effective treatment options. However, the integration of advanced technology in treatment processes, such as telehealth services and mobile applications for self-management, offers new ways to support individuals in remote or underserved locations. Additionally, ongoing research and development are leading to novel therapeutic drugs and interventions, expanding the range of treatment options available.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 556.42 million |
Estimated Year [2024] | USD 587.85 million |
Forecast Year [2030] | USD 835.76 million |
CAGR (%) | 5.98% |
Product: Need for efficient diagnosis to accurately identify BED and any comorbid conditions
The diagnostics segment for binge eating disorder primarily involves psychological evaluations, physical exams, and laboratory tests. Accurate and early diagnostic tools are crucial for understanding the patient's eating behaviors, history, and mental health status.
The treatment segment for binge eating disorder comprises pharmacotherapy, psychotherapy, and support groups/counseling. Anticonvulsants, such as topiramate, stabilize mood and possibly reduce food cravings through modulation of neurotransmitter pathways in the brain. Antidepressants, including selective serotonin reuptake inhibitors (SSRIs), are commonly used in the treatment of BED, reflecting the comorbidity of BED with mood disorders. The effectiveness of antidepressants in treating BED is theorized to come from their ability to increase serotonin levels, which may influence mood and potentially reduce compulsive eating behaviors. Cognitive behavioral therapy (CBT) focuses on identifying and changing negative thought patterns and behaviors related to binge eating. CBT helps individuals develop coping strategies to control urges to binge, improve self-esteem, and address co-occurring psychological issues such as depression or anxiety. Dialectical behavior therapy (DBT) is a form of cognitive-behavioral therapy that integrates strategies for mindfulness, emotion regulation, distress tolerance, and interpersonal effectiveness. Its primary focus in BED treatment is helping individuals understand and accept their binge-eating behaviors while simultaneously working on changing these behaviors by building coping skills. Interpersonal psychotherapy (IPT) is a time-limited treatment focused on improving interpersonal functioning and communication skills. It explores underlying interpersonal issues that may trigger binge eating episodes, such as unresolved grief, role disputes, role transitions, and interpersonal deficits.
End-User: Higher preferences for hospitals with comprehensive services, essential for addressing the complex needs of BED patients
Hospitals have a crucial role in the treatment and management of binge eating disorder (BED). As end-users, hospitals adopt a multidisciplinary approach to provide comprehensive care, including medical evaluation, nutritional counseling, psychiatric support, and behavioral therapies. Hospitals are preferred for their capacity to offer immediate medical care combined with follow-up treatment plans. Specialty clinics focused on eating disorders offer targeted and personalized care for individuals with binge eating disorders. These clinics provide an array of specialized treatment options, including cognitive-behavioral therapy (CBT), interpersonal psychotherapy (IPT), dialectical behavior therapy (DBT), and medication management tailored specifically to BED. The specialized nature of these clinics allows for a deeper understanding of the disorder, fostering an environment where patients can receive focused care from professionals highly experienced in treating eating disorders.
Regional Insights
In the Americas, increasing awareness and diagnosis of binge eating disorder has resulted in significant adoption of both pharmacological and non-pharmacological treatments, which has led to a robust market performance in this region. The FDA's approval of medications specific to BED and coverage of therapy sessions by insurance companies contribute to the growth. In the EMEA region, the market performance is influenced by a growing awareness of BED as a distinct medical condition. Europe, with advanced healthcare systems and widespread availability of treatment options, including cognitive behavioral therapy (CBT), has been contributing majorly to the growth of EMEA's binge eating disorder market. The Middle East and Africa, however, exhibit slower growth owing to limited awareness and healthcare infrastructure. The APAC region is witnessing a gradual increase in the recognition of binge eating disorder and its treatment market, driven by the rise of mental health awareness. However, the region faces challenges such as cultural stigmas around mental health and a paucity of specialized healthcare providers.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Binge Eating Disorder Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Binge Eating Disorder Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Binge Eating Disorder Market, highlighting leading vendors and their innovative profiles. These include Alsana, Inc., Alvogen, Amneal Pharmaceuticals, Inc., Apotex Inc., Ascent Pharmaceuticals, Inc., BALANCE Eating Disorder Treatment Center, Carolina House Eating Disorder Treatment Center, Center for Change, Eating Disorders Treatment Center, Eating Recovery Center, Equip Health Medical, P.C., Hikma Pharmaceuticals PLC, Mallinckrodt PLC, Monte Nido & Affiliates Holdings, LLC, Montecatini Eating Disorder Treatment Center, Natural Food Therapy, Red Oak Recovery, Rhodes Pharmaceuticals L.P. by Purdue Pharma L.P., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, TalktoAngel, The London Centre for Eating Disorders and Body Image Ltd., Timberline Knolls Residential Treatment Center, Veritas Collaborative, and Viatris Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Binge Eating Disorder Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Binge Eating Disorder Market?
3. What are the technology trends and regulatory frameworks in the Binge Eating Disorder Market?
4. What is the market share of the leading vendors in the Binge Eating Disorder Market?
5. Which modes and strategic moves are suitable for entering the Binge Eating Disorder Market?
T